Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry

Fabiola Atzeni, Piercarlo Sarzi-Puttini, Costantino Botsios, Antonio Carletto, Paola Cipriani, Ennio Giulio Favalli, Elena Frati, Valentina Foschi, Stefania Gasparini, Annarita Giardina, Elisa Gremese, Florenzo Iannone, Marco Sebastiani, Tamara Ziglioli, Domenico Biasi, Clodoveo Ferri, Mauro Galeazzi, Roberto Gerli, Roberto Giacomelli, Roberto GorlaMarcello Govoni, Giovanni Lapadula, Antonio Marchesoni, Fausto Salaffi, Leonardo Punzi, Giovanni Triolo, Gianfranco Ferraccioli

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register.
Original languageEnglish
Pages (from-to)225-229
Number of pages5
JournalAutoimmunity Reviews
Volume12
DOIs
Publication statusPublished - 2012

Keywords

  • anti-TNF therapy
  • rheumatoid arthritis

Fingerprint

Dive into the research topics of 'Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry'. Together they form a unique fingerprint.

Cite this